TY - JOUR
T1 - International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives
AU - Marthin, June K
AU - Lucas, Jane S
AU - Boon, Mieke
AU - Casaulta, Carmen
AU - Crowley, Suzanne
AU - Destouches, Damien M S
AU - Eber, Ernst
AU - Escribano, Amparo
AU - Haarman, Eric
AU - Hogg, Claire
AU - Maitre, Bernard
AU - Marsh, Gemma
AU - Martinu, Vendula
AU - Moreno-Galdó, Antonio
AU - Mussaffi, Huda
AU - Omran, Heymut
AU - Pohunek, Petr
AU - Rindlisbacher, Bernhard
AU - Robinson, Phil
AU - Snijders, Deborah
AU - Walker, Woolf T
AU - Yiallouros, Panayiotis
AU - Johansen, Helle Krogh
AU - Nielsen, Kim G.
PY - 2021
Y1 - 2021
N2 - Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement.Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process.Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic.Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.
AB - Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement.Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process.Results We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic.Conclusion The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.
KW - CYSTIC-FIBROSIS
KW - PSEUDOMONAS-AERUGINOSA
KW - STENOTROPHOMONAS-MALTOPHILIA
KW - RECOMMENDATIONS
KW - MULTICENTER
KW - FOUNDATION
KW - EFFICACY
KW - CARE
U2 - 10.1183/23120541.00301-2021
DO - 10.1183/23120541.00301-2021
M3 - Journal article
C2 - 34350277
SN - 2312-0541
VL - 7
JO - ERJ Open Research
JF - ERJ Open Research
IS - 3
M1 - 00301-2021
ER -